Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2869)	3/27/2020 12:54:17 AM
From: CuttingEdge Bio	Read Replies (1) \| Respond to of 3557

Well, neither of my comments were sarcastic. This is from the full text of marmoset study "One indication that penetration of mAb into the lung might at least partially explain the limited reduction in lung viral loads we observed, is the fact that viral loads in almost all other tissues were lower in all four treatment groups than in the control animals. It would thus be of interest to investigate alternative routes of administration such as nebulization to maximize the concentration of mAbs in the lungs (Respaud et al., 2015)." Idea would seem to be by getting Ab into lungs, could prevent virus from infecting additional lung cells and shut off that process of spreading, as it did in the other tissues. As for the study you cite here, the relevance of this finding seems to me that someone who might have developed anti-SARS or anti-MERS antibodies previously, if they tried to use those to treat Covid19, it would fail spectacularly and would not neutralize the virus. Am I missing anything else about this that we should take away from it?